Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis

NCT03999788 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.

NCT NCT03999788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03999788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis
Lead sponsor
Neuromed IRCCS
Phase
Not applicable
Overall status
Unknown status
Start date
December 10, 2019
Completion date
December 28, 2025
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, spasticity